(Total Views: 608)
Posted On: 05/20/2020 7:07:38 PM
Post# of 153905
I understand and respect your opinion.
From my perspective, uplisting had been a back-burner item for some time -- but recently became a front-burner item. Around a week ago, NP and Michael Mulholland mentioned an update in approximately 2 weeks.
I think the company needs the money to move forward with COVID trials, approval, and drug procurement. Remember, aside from Mexico, there are now 3-Arm trials being anticipated. And, there might be 3-Arm related, or unrelated trials in the UK/Ireland. As things progress, there will likely be many other trials in other parts of the world.
I don't think CytoDyn can run-on-fumes or coast-to-the-end of the COVID finish line -- hoping that government or NGO funding will arrive in time. Lack of sufficient funds also places them in a non-leveraged position in terms of the many negotiations that will soon take place.
Lastly, I imagine it would be vastly more beneficial for this capital raise to be based on pre-COVID valuations. And, selfishly, I hope we are uplisted BEFORE a COVID approval as retail and institutional money will flow much more freely than if we are still OTC.
Just my thoughts.
From my perspective, uplisting had been a back-burner item for some time -- but recently became a front-burner item. Around a week ago, NP and Michael Mulholland mentioned an update in approximately 2 weeks.
I think the company needs the money to move forward with COVID trials, approval, and drug procurement. Remember, aside from Mexico, there are now 3-Arm trials being anticipated. And, there might be 3-Arm related, or unrelated trials in the UK/Ireland. As things progress, there will likely be many other trials in other parts of the world.
I don't think CytoDyn can run-on-fumes or coast-to-the-end of the COVID finish line -- hoping that government or NGO funding will arrive in time. Lack of sufficient funds also places them in a non-leveraged position in terms of the many negotiations that will soon take place.
Lastly, I imagine it would be vastly more beneficial for this capital raise to be based on pre-COVID valuations. And, selfishly, I hope we are uplisted BEFORE a COVID approval as retail and institutional money will flow much more freely than if we are still OTC.
Just my thoughts.
(5)
(0)
